United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) CEO Martine A. Rothblatt sold 3,600 shares of the company's stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $237.91, for a total value of $856,476.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at $30,928.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
United Therapeutics Stock Up 0.4 %
Shares of United Therapeutics stock opened at $237.93 on Friday. The stock's fifty day moving average is $231.71 and its 200-day moving average is $228.55. The firm has a market capitalization of $11.20 billion, a PE ratio of 11.99 and a beta of 0.52. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. United Therapeutics Co. has a 12-month low of $204.44 and a 12-month high of $261.54.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.28 by $0.08. The company had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. United Therapeutics's revenue for the quarter was up 25.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.67 earnings per share. Equities analysts anticipate that United Therapeutics Co. will post 23.45 earnings per share for the current year.
Wall Street Analyst Weigh In
Dems have chosen Biden replacement?
From Paradigm Press | Ad
On November 16, 2023…
Joe Biden accidentally revealed the name of the candidate…
Who will replace him in the 2024 presidential election.
See who it is HERE.
UTHR has been the topic of a number of research reports. Leerink Partnrs restated an "outperform" rating on shares of United Therapeutics in a report on Monday, February 5th. StockNews.com lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, April 11th. The Goldman Sachs Group raised United Therapeutics from a "sell" rating to a "neutral" rating and increased their target price for the stock from $213.00 to $215.00 in a report on Monday, February 12th. HC Wainwright reaffirmed a "buy" rating and set a $300.00 target price on shares of United Therapeutics in a report on Thursday, February 22nd. Finally, Wedbush restated an "outperform" rating and set a $308.00 price objective on shares of United Therapeutics in a research report on Thursday, February 22nd. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $292.67.
View Our Latest Report on UTHR
Institutional Investors Weigh In On United Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the stock. DekaBank Deutsche Girozentrale raised its position in shares of United Therapeutics by 54.4% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 94,643 shares of the biotechnology company's stock worth $20,617,000 after purchasing an additional 33,338 shares during the period. Nordea Investment Management AB raised its position in shares of United Therapeutics by 155.2% during the fourth quarter. Nordea Investment Management AB now owns 38,698 shares of the biotechnology company's stock worth $8,427,000 after purchasing an additional 23,532 shares during the period. Louisiana State Employees Retirement System acquired a new stake in shares of United Therapeutics during the fourth quarter worth $2,903,000. O Shaughnessy Asset Management LLC raised its position in United Therapeutics by 4.9% during the third quarter. O Shaughnessy Asset Management LLC now owns 2,300 shares of the biotechnology company's stock valued at $520,000 after buying an additional 107 shares during the period. Finally, DnB Asset Management AS acquired a new position in United Therapeutics during the third quarter valued at $3,340,000. 94.08% of the stock is owned by institutional investors and hedge funds.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
